NCT02595866 - Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 4, 2016

Primary Completion Date

October 4, 2023

Study Completion Date

March 25, 2024

Conditions

AIDS-Related Non-Hodgkin LymphomaClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Hepatocellular CarcinomaHIV InfectionKaposi SarcomaLocally Advanced Lung Non-Small Cell CarcinomaLocally Advanced Malignant Solid NeoplasmMetastatic Lung Non-Small Cell CarcinomaMetastatic Malignant Solid NeoplasmMetastatic MelanomaNon-Hodgkin LymphomaRecurrent Classic Hodgkin LymphomaRecurrent Malignant NeoplasmRefractory Classic Hodgkin LymphomaRefractory Malignant NeoplasmStage III Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8Unresectable Melanoma

Interventions

DRUG

Antiretroviral Therapy

Given PO

PROCEDURE

Biopsy

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT or PET/CT

BIOLOGICAL

Pembrolizumab

Given IV

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

Trial Locations (12)

10016

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York

10029

Mount Sinai Hospital, New York

14263

Roswell Park Cancer Institute, Buffalo

20892

National Institutes of Health Clinical Center, Bethesda

21201

University of Maryland/Greenebaum Cancer Center, Baltimore

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

35233

University of Alabama at Birmingham Cancer Center, Birmingham

70112

Louisiana State University Health Science Center, New Orleans

94110

Zuckerberg San Francisco General Hospital, San Francisco

94143

UCSF Medical Center-Parnassus, San Francisco

98109

FHCC South Lake Union, Seattle

06520

Yale University, New Haven

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH